?Structure-based design of novel Lassa virus glycoproteins for vaccine development? ABSTRACT Lassa fever is an often-fatal viral hemorrhagic fever (VHF) that is endemic in West Africa, and a significant threat to public health with hundreds of thousands of annual infections. There are no approved vaccines or therapeutics for human use. The potential for further geographic expansion of the rodent reservoirs, the ease of procurement and weaponization of the virus, the frequent importation to North America and Europe, and the recent emergence of novel strains in densely populated Nigeria necessitate development of broadly reactive, fast-acting, protective vaccines. We recently determined the structure of the LASV glycoprotein trimer in complex with neutralizing monoclonal antibodies (MAbs) derived from Lassa fever survivors. This ground-breaking structure is the first prefusion trimer for the entire arenavirus family. This application will test the hypothesis that this newly determined structure can guide design of novel LASV glycoproteins that rapidly elicit broadly protective immune responses against current, antigenically diverse virus lineages. We will now use this novel crystal structure as a design template for further stabilization of native trimers for vaccine development. The proposed project will build on the success of a promising recombinant vesicular stomatitis virus (rVSV) Ebola platform already in West African Ebola clinical trials. In studies proposed under Milestone 1, we will produce a set of genetically modified, structurally stable LASV GPC constructs that mimic native prefusion trimers and effectively present broadly neutralizing epitopes. We will construct, validate and scale up a replication-competent, single-injection bivalent or trivalent rVSV vaccine candidate expressing optimized LASV GPC and EBOV GP in Milestone 2.
The aim of Milestone 3 is to down-select LASV GPC constructs that elicit broad and rapid immunogenicity and superior vaccine efficacy in an outbred guinea pig model of lethal Lassa fever. In Milestone 4, we will demonstrate that the most effective LASV GPC-expressing vaccine candidate elicits protection against diverse lineages of LASV in cynomolgus macaques. At the conclusion of the proposed program we will enter pre-clinical evaluation of a first-in-class bivalent vaccine for Lassa virus and Ebola virus, the causative agents of two of the world's deadliest hemorrhagic fevers. This application contains proprietary/priviledged information that Tulane University and its subcontractors request not be released to persons outside the Government, except for the purposes of review and evaluations.
?Structure-based design of novel Lassa virus glycoproteins for vaccine development? NARRATIVE We recently determined the first pre-fusion structure of the LASV glycoprotein trimer, solved in complex with neutralizing monoclonal antibodies (MAbs) derived from Lassa fever survivors. This application will test the hypothesis that this newly determined structure, the first prefusion trimer for any arenavirus, can guide design of novel LASV glycoproteins to rapidly elicit broadly protective immune responses against the current antigenically diverse lineages of the virus. At the conclusion of the proposed program, we will enter pre- clinical evaluation of a broadly protective Lassa virus vaccine and a bivalent Lassa-Ebola vaccine.
| Boisen, Matthew L; Hartnett, Jessica N; Shaffer, Jeffrey G et al. (2018) Field validation of recombinant antigen immunoassays for diagnosis of Lassa fever. Sci Rep 8:5939 |
| Hastie, Kathryn M; Zandonatti, Michelle A; Kleinfelter, Lara M et al. (2017) Structural basis for antibody-mediated neutralization of Lassa virus. Science 356:923-928 |
